Information Provided By:
Fly News Breaks for December 30, 2019
Dec 30, 2019 | 15:47 EDT
BTIG analyst Robert Hazlett increased his probability of success to 85% from 75% and his peak U.S. sales estimate to over $300M from $175M for AXS-07 for the treatment of acute migraine after Axsome announced positive data from its Phase 3 MOMENTUM study. Hazlett raised his price target on Axsome shares to $114 from $97 and keeps a Buy rating on the stock.
News For AXSM From the Last 2 Days
There are no results for your query AXSM